Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction
Xiaogang Zhu, Xialing Li, Lingxuan Zhu, Zichuan Tong, Xiuying Xu · 2024
Read Angiotensin Receptor–Neprilysin Inhibitor in Heart Failure Patients With Renal Dysfunction by Xiaogang Zhu, Xialing Li, Lingxuan Zhu, Zichuan Tong, Xiuying Xu (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11554417.txt.
Description
Xiaogang Zhu and four co-authors review a heart failure drug for hard cases where the kidneys are failing too. Heart and kidney disease feed each other, and treatment helping one organ can strain the other. The drug, sacubitril/valsartan, pairs a vessel-relaxing blocker with an enzyme inhibitor, and trials suggest it slows the decline of kidney filtration better than an older single drug.
The catch is safety: in patients whose kidneys struggle, strong proof is missing that the drug avoids raising potassium or worsening kidney function. Reports of kidney protection keep appearing, but the evidence base stays thin. The authors recommend a careful balance of benefit and risk for each patient, guided by published experience and teams spanning cardiology and nephrology. They close by calling for studies of the heart-kidney crosstalk, so future guidance can rest on mechanism rather than habit.
Catalog record
| CREATOR | Xiaogang Zhu, Xialing Li, Lingxuan Zhu, Zichuan Tong, Xiuying Xu |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 35 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |